Significance And Clinical And Pathological Features Of Akt2and HER2Protein Expression In Gastric Cancer

PurposeGastric cancer is a common clinical malignant tumors, the5-year survival rate of only10%. Gastric generation, development, invasion and metastasis and cancer cells abnormal gene expression and amplification in close contact, molecular targeted therapy because it can effectively inhibit tumor cell growth, proliferation, and then control the gastric cancer development by clinical widely attention. However, clinical yet found a reliable biological markers for the diagnosis of gastric malignancy and prognostic evaluation, as well as a lack of the ideal biological treatment target.Human epidermal growth factor receptor2(Human Epidermal Growth Factor Receptor, HER2) cell signaling pathways important initiation factor on the proliferation of cancer cells, differentiation and apoptosis play an important role in clinical targeted cancer therapy research hotspot biomarkers. HER2in tumorigenesis, facilitation role in the development process, the role of drug resistance is mainly dependent on the activation of the PI3K/Akt signaling pathway, Akt2gene expression and the development of malignant tumors and metastasis are closely linked. Anti-HER2expression in breast cancer clinical research has been expanded in-depth, but the mechanism and the role of its treatment of gastric cancer is still in the exploratory stage. In this study, using immunohistochemistry assay in patients with gastric cancer Akt2and HER2protein expression, and analysis of the relationship between HER2expression and clinicopathological features of gastric cancer, to provide an objective basis for clinical diagnosis and treatment of gastric cancer. MethodsSelect85cases diagnosed by clinical pathological examination from June2011to June2012xxxx Hospital of primary gastric cancer patients and the same period in healthy subjects and50patients as research subjects.85patients with gastric cancer,58males and27females; ages38-82years old, average (58.5±14.8) years. The Lauren type:diffuse type47cases,32cases of intestinal-type, mixed six cases. Histological type:tubular adenocarcinoma,68cases, seven cases of signet ring cell carcinoma, papillary adenocarcinoma in5cases,3cases of mucinous adenocarcinoma, undifferentiated carcinoma in2cases. Degree of differentiation:poorly differentiated carcinoma in44cases, in well-differentiated carcinoma41cases. Regional lymph node metastasis:30cases without lymph node metastasis, lymph node metastasis in55cases. Depth of invasion:assault and serosa in38cases,47cases of serosal invasion.:Clinical stage I,39cases of stage II, III period, IV46cases. Tumor size:<5cm52patients=5cm33cases. Tumor:stomach (antrum, gastric body) of63cases,22cases of the connection portion of the stomach and esophagus (gastric fundus, cardia)50healthy subjects were selected as a control group, endoscopy biopsy gastric mucosa showed no abnormality. Including33males and17females cases; age37-80years, mean (57.6±13.6) years old.Two groups using immunohistochemistry SP method detected two groups of patients with gastric tissue Akt2HER2protein expression and summed HER2expression in patients with gastric cancer, gender, age, tumor size, tumor location, TNM stage, invasion and lymph node metastasis and pathological features; using SPSS17.0software package for statistical analysis, measurement data using t test, count data using χ2test, P<0.05for the difference was statistically significant data.Results1、Akt2positive expressionThe the gastric group Akt2positive expression in57cases, accounting for67.06%; healthy group Akt2positive expression of the three cases, accounting for6.00%, two sets of-Akt2positive expression expression rates compare χ2=47.5343, P<0.01.2、HER2positive expression(1) Gastric cancer group HER-2positive expression in18cases, accounting for21.18%; health physical examination groups HER-2positive expression cases, accounting for2.00%, the two sets of HER-2positive expression rate χ2=9.5730, P <0.01。3、Expression of HER2-positive gastric cancer patients with clinical pathological features(1)diffuse-type gastric cancer patients with HER2-positive expression rate was8.51%, lower than the43.75%of the intestinal type gastric cancer patients (χ2=13.4378, P<0.01).(2) poorly differentiated gastric cancer patients with HER2-positive expression rate of11.36%,31.71%below the high school differentiated gastric cancer patients (χ2=9.3191, P<0.01).(3) the location of the tumor in the gastric antrum, body and other parts of stomach cancer in patients with HER2-positive expression rate of7.94%, lower than the location of the tumor in the cardia, gastric and other parts of the gastroesophageal junction cancer patients59.09%(χ2=22.5896, P<0.01);(4) without lymph node metastasis of gastric cancer patients with HER2-positive expression rate of6.67%, lower than the29.09%of the patients with lymph node metastasis (χ2=5.8478, P<0.05).(5) Ⅰ Phase Ⅱ gastric cancer patients with HER2-positive expression rate was2.56%, lower than the phase III IV gastric cancer patients36.96%(χ2=14.9561, P <0.01).(6) The tumor does not infringe the serosa of gastric cancer patients with HER2positive expression rate was18.42%and23.40%of the serosal gastric cancer patients with tumor invasion of the difference was not statistically significant (χ2=.3126, P <0.01).(7) tumor diameter<5cm gastric cancer patients with HER2positive expression rate of15.58%, with30.03%of the tumor diameter=5cm gastric cancer patients the difference was not statistically significant (χ2=2.6917, P<0.01).4、gastric carcinoma of Akt2and HER2expression correlationIn85patients with gastric cancer, Akt2HER2-positive expression in17cases, accounting for20.00%; negative co-expression of the27cases,31.76%; of Akt2-positive and HER2-negative in40cases, accounting for47.06%; Akt2negative HER2-positive cases, accounting for1.18%. Of Akt2with HER2expression in gastric cancer tissues correlation (r=0.249, P<0.05).Conclusions1、in patients with gastric cancer Akt2of HER2protein positive expression rate was significantly higher, HER-2with Akt2positive expression was positively correlated.2、HER-2positive expression with tumor site, histological type, tumor differentiation, lymph node metastasis and organizations staging. Tumor in gastroesophageal joints in patients with HER2-positive expression rate in the tumor in the gastric antrum, body parts of patients; intestinal type gastric cancer patients with HER2-positive expression rate in diffuse-type gastric cancer patients; moderately differentiated gastric cancer patients with HER2-positive expression higher than poorly differentiated gastric cancer patients; lymph node metastasis in gastric cancer patients with HER2-positive expression rate in patients with gastric cancer without lymph node metastasis; Ⅲ/Ⅳ patients with gastric cancer’ by HER2-positive expression rate in a phase Ⅰ/Ⅱ gastric cancer patients.3、Gastric cancer patients with HER2positive expression of Akt2protein positive expression was positively correlated.